Last updated: February 15, 2026
What Is the Current Market Position of NDC 50458-0639?
NDC 50458-0639 is marketed as Recarbrio (imipenem-cilastatin-relebactam). It is an antibiotic used to treat complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired pneumonia including ventilator-associated pneumonia (VAP). The drug is manufactured by Merck & Co. Inc.
Recarbrio entered the market in 2019, during a period of growing antimicrobial resistance. It is positioned as a broad-spectrum, beta-lactam/beta-lactamase inhibitor combination targeting multidrug-resistant infections. Its primary competitors include Pfizer’s Zerbaxa (cefepime-zidebactam), AstraZeneca’s Doribax (doripenem), and generic formulations of carbapenems.
What Is Market Size and Demand for Recarbrio?
Market Drivers
- Antimicrobial resistance (AMR): Rising AMR cases boost demand for new antibiotics like Recarbrio.
- Hospital-acquired infections: Increased incidence of cUTI, cIAI, VAP sustains clinical use.
- Limited competition: As a newer product, Recarbrio faces fewer direct competitors, pending patent protections.
Market Estimates
- Global Antibiotics Market Size (2022): USD 49.3 billion [1].
- Hospital-Acquired Infection Treatment Segment (2022): USD 23 billion, with growth forecast at 4.8% CAGR through 2030 [2].
- Recarbrio's U.S. Market Share (2022): Estimated at 10–15% of antibiotics for hospital-resistant infections, due to early adoption by major healthcare providers.
Prescriber Adoption
- Rapid adoption in leading academic medical centers.
- Inclusion in guidelines, such as Infectious Disease Society of America (IDSA) recommendations, enhances uptake.
- Reimbursed by Medicare and Medicaid, maintaining access.
What Are Key Price Points and Cost Dynamics?
Current Pricing
- List Price (U.S.): Approximately USD 3,500–4,500 per treatment course.
- Average Wholesale Price (AWP): USD 4,200 per course [3].
- Reimbursement Rate: Varies by payer; hospitals often procure at discounted rates through negotiations, estimated at 20–30% off AWP.
Cost Breakdown
- Drug acquisition cost: 60–70% of total treatment cost.
- Hospital administration costs: 20–25%, given IV administration and inpatient setting.
- Laboratory and follow-up testing: Remaining 5–10%.
Price Trends and Projections
- Stability (2023–2025): Prices expected to hold due to limited interchangeable options and patent protections.
- Post-Patent Expiry (2028): Potential price reduction of 20–40% due to biosimilar or generic entry if patent barriers are overcome or patent challenges succeed.
How Are Market Dynamics Expected to Evolve?
Patent and Regulatory Landscape
- Merck's patent for Recarbrio expires around 2028.
- Patent extensions or new formulations could delay generic entry.
- Emerging biosimilar candidates may target the marketed formulation if regulatory pathways permit.
Competitive Landscape
- New antibiotics entering the pipeline could influence Recarbrio’s market share.
- Regulatory approvals for combination therapies may alter demand dynamics.
Pricing Strategy Outlook
- Merck likely maintains premium pricing reflecting R&D investments.
- Contractual discounts and supply agreements will influence net prices.
- Pricing remains sensitive to hospital budgets and antimicrobial stewardship policies.
Summary of Market and Price Outlook
| Aspect |
2023–2025 |
2026–2028 |
Post-2028 |
| Market Demand Growth |
Moderate, driven by AMR and hospital infections |
Accelerates as resistance patterns solidify |
Potential decline due to patent expiry and generics |
| Price Trends |
Stable, slight upward pressure from inflation |
Stable with potential negotiation leverage |
20–40% decrease expected with generic entry |
| Competitive Pressure |
Low, limited alternatives |
Slight increase as pipeline matures |
Increased, with biosimilar and generic options |
Key Takeaways
- Recarbrio (NDC 50458-0639) holds a niche in resistant infection treatment, with steady demand driven by antimicrobial resistance.
- Pricing remains high, anchored in hospital procurement practices and limited competition.
- Market size growth aligns with global AMR trends, but drug price reductions are anticipated post-patent expiration.
- Upcoming patent expiry around 2028 presents a pivotal point for price and market share adjustments.
- Competitive and pipeline developments could influence long-term market positioning.
FAQs
1. What factors influence the pricing of Recarbrio?
Reimbursement negotiations, hospital procurement discounts, patent status, competitive pressures, and drug demand influence pricing.
2. How does Recarbrio compare price-wise to competitors?
Recarbrio’s treatment course costs approximately USD 3,500–4,500, higher than some older antibiotics but justified by its activity against resistant strains. Competitors like Zerbaxa have similar price ranges.
3. When is patent expiration expected for Recarbrio?
Merck’s patent coverage is expected to expire around 2028, after which biosimilar or generic versions could enter the market.
4. What is the potential impact of generics on Recarbrio’s market share?
Entry of generics could reduce prices by 20–40% and significantly decrease Merck’s market share unless the innovator maintains competitive advantages or obtains new patents for improved formulations.
5. Which regions present growth opportunities for Recarbrio?
The U.S. remains the primary market, with expanding use in Europe and select Asia-Pacific countries as antimicrobial resistance escalates globally.
Sources
[1] MarketWatch, "Global Antibiotics Market Size," 2022.
[2] Grand View Research, "Hospital-Acquired Infections Treatment Market," 2022.
[3] Red Book Online, "Average Wholesale Price (AWP) for Recarbrio," 2023.
